180 Life Sciences

At 180 Life Sciences, we're driven by a steadfast commitment to developing groundbreaking therapeutics that address unmet medical needs in inflammation, fibrosis, and pain. Our innovative pipeline holds the potential to transform the lives of millions. Keep up with our developments here: https://bit.ly/3Nv63vu #Science #LifeSciences #antiTNF

Post operative cognitive decline (POCD) is a common neuropsychiatric syndrome, associated with poor functional outcomes, reduced quality of life and longer hospital stays. Anti-TNF could have the potential to unlock new hope for post operative cognitive decline (POCD) as a preventative therapy. Learn more about 180 Life Sciences’ anti-TNF program: https://bit.ly/3N2Jm0e #Science #LifeSciences #antiTNF

180 Life Sciences’ synthetic #CBD analogs (SCAs) program is one of three therapeutics families in our pipeline targeting multiple indications. We believe that SCAs have the potential to fulfill unmet needs for orally available, relatively safe, anti-inflammatory drugs, especially those with analgesic properties. More details on our primary development targets here: https://bit.ly/426741K #Science #LifeSciences #Biotech

Our leadership team is led by scientific pioneers, experienced operators, and seasoned executives. 180 Life Sciences’ CFO, Ozan Pamir, brings in-depth experience in investment banking and capital markets. In case you missed his latest interview, read more via StrategicCFO360: https://bit.ly/477eRyT #Science #Biotech #CFO

180 Life Sciences (Nasdaq: ATNF) has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Read here for more details: https://bit.ly/3GtsixB #BusinessUpdate

Pre-revenue #healthcare, #lifesciences, and #biotechnology companies face a significant challenge: securing the substantial capital required to navigate the lengthy product development cycle. 180 Life Sciences CFO Ozan Pamir, CFA speaks with Strategic Finance Magazine’s editor, Dan Butcher, to share insight on finance leaders’ key role in building start-ups, the importance of vetting potential financial services partners and building banking relationships, and how to leverage financing to fund R&D and achieve strategic objectives. Read the insightful interview here: https://bit.ly/47DLG74 #Biotech #Science IMA | Institute of Management Accountants

There are currently no approved treatment options for those patients who present with symptomatic, early-stage #DupuytrensDisease. 180 Life Sciences’ lead program, focused on early-stage Dupuytren’s Disease, has demonstrated significant efficacy in clinical trials. We’re working on paving the way for a breakthrough treatment for this debilitating disease. Learn more: https://bit.ly/3N2Jm0e #Science #DupuytrensDisease #Biotech #AntiTNF

Tune in! CEO Dr. James Woody joined the Empowered Patient Podcast with host Karen Jagoda to discuss 180 Life Sciences’ vision for safer pain and inflammation management. He also dives into the company’s research on the potential of synthetic #cannabinoid analogs (SCAs). Listen here: https://bit.ly/3uG1nvR #LifeSciences #AntiTNF #Science #Biotech #PainManagement

Chronic pain is an unfortunate condition caused by inflammation. Learn how 180 Life Sciences is harnessing the power of #cannabinoids and developing treatments for inflammatory diseases and pain through our SCAs program: https://bit.ly/3QLTM6j #Science #LifeSciences #Biotech

180 Life Sciences (Nasdaq: ATNF) announces review of strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options. Read the full news release here: https://bit.ly/3QX6lf3 #BusinessUpdate